Trastuzumab (Herceptin) PBPK-TMDD Simulator
Indication: HER2-positive breast cancer
Simulate trastuzumab pharmacokinetics with HER2 target shedding. Explore how circulating ECD-HER2 antigen creates a drug sink, trough concentration collapse at high ECD levels, HER2 receptor occupancy, and dose optimization strategies for high-shedding patients.
Drug Overview
Clinical Context
- Molecular Target
- HER2/ErbB2
- Drug Class
- Anti-HER2 Monoclonal Antibody
- Therapeutic Area
- Oncology
- Indication
- HER2-positive breast cancer
- Route of Administration
- IV
Model Information
- Model Type
- Minimal PBPK-TMDD
- Reference
- Li Z, Shah DK. CPT Pharmacometrics Syst Pharmacol. 2014;3(4):e88
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
Pharmacokinetic Parameters
PK Parameters
| Parameter | Value |
|---|---|
| Q | 1.03 L/day |
| CL | 0.225 L/day |
| Vc | 3.11 L |
| Vp | 3.57 L |
Parameters sourced from published population pharmacokinetic models. Values represent typical population estimates; individual patient parameters may vary.
About This Simulator
This interactive pharmacokinetic simulator for Trastuzumab (Herceptin) PBPK-TMDD allows you to explore concentration-time profiles under different dosing scenarios. The underlying Minimal PBPK-TMDD model characterizes the pharmacokinetics of this anti-her2 monoclonal antibody following iv administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Trastuzumab (Herceptin) PBPK-TMDD PK simulator?
This is a free, interactive pharmacokinetic simulator for Trastuzumab (Herceptin) PBPK-TMDD used in HER2-positive breast cancer. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Trastuzumab (Herceptin) PBPK-TMDD belong to?
Trastuzumab (Herceptin) PBPK-TMDD is classified as a Anti-HER2 Monoclonal Antibody that targets HER2/ErbB2. It is used in the Oncology therapeutic area.
What route of administration does this model simulate?
This simulator models IV administration of Trastuzumab (Herceptin) PBPK-TMDD. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a Minimal PBPK-TMDD model. PBPK models use physiological parameters to predict drug distribution across tissues and organs.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
What is the half-life of Trastuzumab (Herceptin) PBPK-TMDD?
Based on the published model parameters, the elimination half-life of Trastuzumab (Herceptin) PBPK-TMDD is approximately ~28 days (low ECD); 0.3 days (high ECD). Note that half-life can vary based on patient-specific factors such as body weight, organ function, and genetic polymorphisms.
What is the clearance of Trastuzumab (Herceptin) PBPK-TMDD?
The clearance (CL) of Trastuzumab (Herceptin) PBPK-TMDD is approximately [object Object]. Clearance represents the volume of plasma from which drug is completely removed per unit time and is a key determinant of drug exposure and steady-state concentrations.
Related Simulators
PopPK of Docetaxel
capecitabine
PBPK-PD of ADCs
Trodelvy PopPK
Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload
Datroway PopPK
Locally advanced or metastatic non-squamous NSCLC (TROPION-Lung08), HR+/HER2-low/negative metastatic breast cancer (TROPION-Breast01), and triple-negative breast cancer; TROP2-directed ADC with DXd payload
Enhertu PopPK
HER2-positive breast cancer, gastric/gastroesophageal adenocarcinoma, NSCLC
Ready to Simulate?
Launch the Trastuzumab (Herceptin) PBPK-TMDD simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community